We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Sarepta Therapeutics (SRPT) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

Sarepta Therapeutics, Inc. has a 12-month low of $101.15 and a 12-month high of $173.25. The stock has a market cap of $10.06 billion, a P/E ratio of 84.28 and a beta of 0.75.

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, ...